Compass Therapeutics (CMPX) Enterprise Value (2018 - 2026)
Compass Therapeutics recorded quarterly Enterprise Value of -$194.7 million in Q1 2026, up 7.06% quarter-over-quarter from -$209.5 million in Q4 2025, and down 71.98% year-over-year from -$694.8 million in Q1 2025.
Compass Therapeutics' Enterprise Value history runs 9 years deep, the most recent figure standing at -$194.7 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 71.98% year-over-year to -$194.7 million; the TTM figure through Mar 2026 stood at -$194.7 million (down 71.98% YoY), while the FY2025 annual figure was -$209.5 million, down 64.56% from the prior year.
- Enterprise Value came in at -$194.7 million for Q1 2026 at Compass Therapeutics, up from -$209.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$101.5 million in Q2 2025 to a low of -$219.9 million in Q3 2025.
- A 5-year average of -$155.4 million and a median of -$152.5 million in 2023 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value plunged 372.95% in 2022 and surged 35.7% in 2025, its largest moves.
- Compass Therapeutics' Enterprise Value stood at -$186.6 million in 2022, then gained by 18.28% to -$152.5 million in 2023, then advanced by 16.51% to -$127.3 million in 2024, then tumbled by 64.56% to -$209.5 million in 2025, then gained by 7.06% to -$194.7 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$194.7 million, -$209.5 million, and -$219.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | -194.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -194.69 Mn |
| Dec 31, 2025 | -209.47 Mn |
| Sep 30, 2025 | -219.90 Mn |
| Jun 30, 2025 | -101.52 Mn |
| Mar 31, 2025 | -113.20 Mn |
| Dec 31, 2024 | -127.29 Mn |
| Sep 30, 2024 | -118.01 Mn |
| Jun 30, 2024 | -146.23 Mn |
| Mar 31, 2024 | -176.06 Mn |
| Dec 31, 2023 | -152.46 Mn |
| Sep 30, 2023 | -163.70 Mn |
| Jun 30, 2023 | -168.75 Mn |
| Mar 31, 2023 | -175.17 Mn |
| Dec 31, 2022 | -186.56 Mn |
| Sep 30, 2022 | -120.60 Mn |
| Jun 30, 2022 | -132.02 Mn |
| Mar 31, 2022 | -136.40 Mn |
| Dec 31, 2021 | -144.51 Mn |
| Sep 30, 2021 | -25.50 Mn |
| Mar 31, 2021 | -39.70 Mn |
| Dec 31, 2020 | -47.08 Mn |
| Sep 30, 2020 | -55.52 Mn |
| Jun 30, 2020 | -65.37 Mn |
| Mar 31, 2020 | -3,745.00 |
| Dec 31, 2019 | -25.30 Mn |
| Sep 30, 2019 | -882.00 |
| Jun 30, 2019 | -4,866.00 |
| Mar 31, 2019 | -4,866.00 |
| Dec 31, 2018 | -4,679.00 |
| Sep 30, 2018 | -2,446.00 |
| Jun 30, 2018 | -7,231.00 |